Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAICS | P22234 | 1/20 | 0.37 |
| ▸ | ESR1 | P03372 | 1/20 | 0.33 |
| ▸ | MET | P08581 | 2/20 | 0.32 |
| ▸ | CDK2 | P24941 | 1/20 | 0.31 |
| ▸ | CACNA1B | Q00975 | 3/20 | 0.30 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13886769 | 0.86 | PAICS (0.32) | PAICSESR1MET | |
| SCHEMBL15626284 | 0.86 | FFAR1 (0.38) | ESR1CACNA1B | |
| SCHEMBL4018429 | 0.85 | ESR1 (0.35) | ESR1CACNA1B | |
| SCHEMBL4018558 | 0.85 | LIMK1 (0.37) | ESR1 | |
| SCHEMBL4016369 | 0.84 | CACNA1B (0.32) | ESR1CDK2CACNA1B | |
| SCHEMBL4018941 | 0.84 | FGFR3 (0.31) | — | |
| SCHEMBL4016367 | 0.83 | ESR1 (0.35) | ESR1CDK2CACNA1B | |
| SCHEMBL4020442 | 0.82 | LIMK1 (0.36) | ESR1 | |
| SCHEMBL4019006 | 0.80 | LIMK1 (0.37) | ESR1 | |
| SCHEMBL4018949 | 0.80 | KCNH2 (0.35) | CACNA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1663241-B1 | 5-ARYLPYRIMIDINES AS ANTICANCER AGENTS | WYETH CORP (US) | 2009-05-27 | — | — | EP | disclosed |
| US-7524849-B2 | Antitumor agents to treat multiple drug resistant tumors; promoters of microtubule polymerization; etherification | WYETH HOLDINGS CORPORATION (US) | 2009-04-28 | — | — | US | disclosed |
| EP-1663241-A1 | 5-ARYLPYRIMIDINES AS ANTICANCER AGENTS | Wyeth Holdings Corporation (US) | 2006-06-07 | — | — | EP | disclosed |
| WO-2005030216-A1 | 5-ARYLPYRIMIDINES AS ANTICANCER AGENTS | WYETH HOLDINGS CORPORATION (US) | 2005-04-07 | — | — | WO | disclosed |
| US-20050075357-A1 | 5-arylpyrimidines as anticancer agents | WYETH (US) | 2005-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050075357-A1 | 5-arylpyrimidines as anticancer agents | DPYD, ABCC1, ARF5 | PAICS 191/4885ESR1 4769/4885MET 419/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.